INS and Hyperglycemia: The primary mechanism involves mitigating diabetic inflammation by inhibiting hyperglycemia-induced damage pathways and restoring insulin sensitivity, which leads to lower levels of inflammatory markers in the serum, visceral and perivascular tissues, as well as within the atherosclerotic plaques [31,32,33,34].